Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) EPS (Basic) (2021 - 2025)

Historic EPS (Basic) for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to -$34465.6.

  • ProQR Therapeutics' EPS (Basic) rose 657.52% to -$34465.6 in Q3 2025 from the same period last year, while for Sep 2025 it was -$34465.6, marking a year-over-year increase of 657.52%. This contributed to the annual value of -$0.35 for FY2024, which is 851.9% up from last year.
  • According to the latest figures from Q3 2025, ProQR Therapeutics' EPS (Basic) is -$34465.6, which was up 657.52% from -$61242.9 recorded in Q2 2025.
  • Over the past 5 years, ProQR Therapeutics' EPS (Basic) peaked at -$0.06 during Q4 2023, and registered a low of -$104500.0 during Q1 2025.
  • In the last 5 years, ProQR Therapeutics' EPS (Basic) had a median value of -$34465.6 in 2025 and averaged -$38359.4.
  • As far as peak fluctuations go, ProQR Therapeutics' EPS (Basic) skyrocketed by 6717.24% in 2023, and later plummeted by 19574.93% in 2025.
  • Quarter analysis of 5 years shows ProQR Therapeutics' EPS (Basic) stood at -$0.28 in 2021, then surged by 34.62% to -$0.19 in 2022, then surged by 67.17% to -$0.06 in 2023, then tumbled by 75.47% to -$0.11 in 2024, then crashed by 32236151.02% to -$34465.6 in 2025.
  • Its EPS (Basic) stands at -$34465.6 for Q3 2025, versus -$61242.9 for Q2 2025 and -$104500.0 for Q1 2025.